No Data
No Data
Novo Nordisk's Wegovy Gets EU Regulator Endorsement to Reduce Heart Risks -- Update
Will it break the duopoly monopoly? The "new star" of weight loss drug Viking's stock price has doubled 2.4 times this year.
Eli Lilly and Co's market cap evaporated by 120 billion US dollars.
Novo Nordisk Shares Decline Amid Competitive Pressure
Is the weight loss drug industry about to change? Viking Therapeutics rose nearly 40% intraday and hit a two-month high.
After communicating with the regulatory institution FDA, USA's Viking Therapeutics is pushing forward the weight-loss candidate drug VK2735 to phase III clinical trials ahead of schedule, potentially bringing the launch time forward by one year. This drug is expected to be injected once a month, which is more convenient than the same miraculous drug from Eli Lilly and Co and Novo Nordisk A/S. The oral version of VK2735 will start mid-term trials in the fourth quarter of this year.
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
Novo Nordisk's weight loss drug Wegovy has received approval from the European Union and can reduce the risk of major heart diseases by 20%.
According to a press release by novo-nordisk a/s, the european medicines agency (EMA) supports the company's use of the weight-loss drug Wegovy to reduce the risk of stroke and heart disease. Analysis suggests that this significantly expands the potential number of benefiting patients.
No Data